Correspondingly, RAS blockers and/or angiotensin converting enzyme (ACE) inhibitors are able to reverse these deleterious effects of angiotensin II by improving insulin sensitivity and pancreatic beta cell function and thus are promising therapeutic targets for DM (Lau et al., 2004[67]; Ribeiro-Oliveira et al., 2008[104]; Wei et al., 2008[134]; Madec et al., 2013[78]; Simoes e Silva et al., 2017[117]). Here, INS is linked to diabetes mellitus.